Observation on Sequential therapy of levofloxacin for community acquired pneumonia
Abstract
OBJECTIVE To observe the efficacy of levofloxacin in treatment of community-acquired pneumonia both in the adminstration of intravenous drip and orl sequential therapy.METHODS 81 patients with community-acquired pneumonia,first in treatment with levofloxacin 0.2g each time,iv.gtt,bid;when the symptoms improved,then divided into two groups:the treatment group and controlled group.48 cases in treatment group,were switched levofloxacin 0.1g each,o.p,bid,course was 4～7d;the other 33 cases were cotrolled group,the original theapic method was continued,and course was 3～6d.RESULTS The efficacy of the two groups have no significant differences(P0.05),CONCLUSION Levofloxacin in both adminstration of intravenous drip and oral sequential therapy to therapy community-acquired pneumonia were as effectively as intravenous drip allover the course.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.